Sequel Med Tech’s Post

Following Novo Nordisk's announcement of Levemir insulin discontinuation in the U.S., we surveyed our database of individuals with diabetes to gauge interest in transitioning from MDI to insulin pumps. Here are the findings from our 24-hour pulse survey: - 21% are considering switching to insulin pumps - 68% prefer switching to another long-acting insulin And for more context, here are some of the written responses we collected: "I want to talk to my doctor before deciding." "I just started taking insulin, I am unsure that my insurance would cover a pump. Otherwise, I would use a pump." "I will switch to a different brand just in case I don't have enough pump supplies." "I was happy with my regimen. But after so many years, I'm wondering if this is the time to try either Tandem or Omnipod instead (it's hard to decide which)." This year, our team dove deep into GLP-1 RA trends, including why patients start, stop, and switch GLP-1 and SGLT2-I treatments. We compiled all of our findings into a comprehensive report that we are offering FREE for a limited time. Download the full report here: https://lnkd.in/eRPYVXFF

The article provides guidance on how to take Ozempic, a medication used to manage type 2 diabetes and aid in weight loss. It emphasizes the importance of following your healthcare provider's instructions regarding the dosage and administration of Ozempic. Typically, the medication is injected once a week, and the dosage may vary depending on individual health conditions and treatment goals. The article also discusses common side effects and precautions associated with Ozempic use, highlighting the need for regular monitoring and communication with your healthcare team to ensure safe and effective treatment. #Health #Discoverybody https://lnkd.in/d7tsh48Q

As an internist, I often get asked, "How long does it take for Ozempic to start working?" The answer varies from patient to patient, but typically, Ozempic, a medication used to manage type 2 diabetes, begins to lower blood sugar levels within a week. However, it may take up to 12 weeks to see its full effect on your A1C levels. Remember, each individual's response to medication is different. Therefore, it's important to consult with your healthcare provider for personalized advice. #InternistInsights #DiabetesManagement #Ozempic #mounjaro I spoke with Ben Michalak at SingleCare about it: https://lnkd.in/eQT_gHsE

Beyond Meds: Embracing Digital Therapeutics for Smarter Diabetes Management The journey with diabetes can be overwhelming, demanding constant vigilance and meticulous self-care. But technology is stepping in, offering a beacon of hope with digital therapeutics (DTx) – software-driven interventions designed to complement traditional treatments. This isn’t just about convenience; DTx is transforming diabetes management, empowering individuals to take control and navigate their health journey more effectively. Learn more at https://lnkd.in/etvMSA5V #digitaltherapeutics #diabetesmanagement

Another milestone for PolTREG. We are announcing positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes (T1D). “At PolTREG, we believe that PTG-007 has the potential to prevent type-1 diabetes, freeing patients of the life-long burden of having to take frequent insulin injections, and the serious long-term complications of the disease. The results of this study are an important step in that direction,” said Prof Piotr Trzonkowski, PolTREG S.A. Chief Executive Officer.   Here are the main findings, found over a period of up to 12 years during which patients were monitored: ☑ Patients who received PTG-007 continued to secrete insulin, while untreated patients in the control group did not, ☑ Safety measures showed no significant difference in the health status of patients who received Treg therapy compared to the control group, ☑ The duration of disease remission was significantly longer in patients who received PTG-007 compared to the control group.   No other company currently can show similar long-term safety results of Treg therapy in T1D. This is a significant competitive advantage, and paves the way for the launch of a pivotal Phase 2/3 study of PTG-007 – a final step before seeking market authorization.   Read our press release here: https://lnkd.in/dNEyDRK7   #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #diabetes #type1diabetes

Large airway wall vascularity in patients with Asthma COPD overlap: a bronchoscopy study https://lnkd.in/eRNG9QWE

Large airway wall vascularity in patients with Asthma COPD overlap: a bronchoscopy study https://lnkd.in/eRNG9QWE

Important long-term clinical data from PolTREG S.A. using #Treg #celltherapy in #type1diabetes.

Large airway wall vascularity in patients with Asthma COPD overlap: a bronchoscopy study https://lnkd.in/eK_UjCYy

Large airway wall vascularity in patients with Asthma COPD overlap: a bronchoscopy study https://lnkd.in/eRNG9QWE